POSITION STATEMENT
USE OF “BIOSIMILAR” INSULINS FOR DIABETES

Background
This Position Statement represents the collective views of the Australian Diabetes Society, the Australian Diabetes Educators Association and Diabetes Australia.

The Therapeutic Goods Administration (TGA) recently approved the first “biosimilar” insulin product for use in Australia – Basaglar insulin.

A “biosimilar” is a copy of a biological molecule that has already been approved for use and has a demonstrated similarity in physiological characteristics, efficacy and safety. The Pharmaceutical Benefits Advisory Committee (PBAC) is considering the PBS listing and use of Basaglar insulin and the option to allow pharmacy level substitution whereby a pharmacist could substitute Basaglar insulin for the originator (Lantus insulin) or vice versa.

Summary of Position Statement
Diabetes Australia, the Australian Diabetes Society and the Australian Diabetes Educators Association are strongly opposed to biosimilar substitution at the pharmacy level due to insufficient evidence of safety.

We support substitution of insulins under appropriate medical supervision and with the involvement of the diabetes healthcare team including diabetes educators and practice nurses.

Over 370,000 Australians with diabetes are currently using insulin therapy and pharmacy level substitution has the potential to seriously disrupt diabetes management for large numbers of people with diabetes. We have particular concerns about the increased risk of hypoglycaemia which may be associated with switching insulins.

Uncertainty for people with diabetes on insulin has been created by reports of apparent confusion within the regulatory system with the TGA reportedly finding that “Replacement of Lantus with Basaglar, or vice versa, should take place only under strict medical supervision” while the PBAC has reportedly adopted a default position of allowing pharmacy level substitution.

We support government objectives to expand affordable access to diabetes medicines and treatments, where it is safe and effective to do so.

Diabetes Australia,
101 Northbourne Avenue, Turner ACT 2612
ABN: 47 008 528 461
Tel: +61 2 6232 3800  E:  admin@diabetesaustralia.com.au
However there has been insufficient consultation with diabetes consumers, consumer organisations and diabetes health professional experts in Australia about this issue.

Evaluation of Biosimilar Insulins
Recent amendments to the National Health Act contained in the National Health Amendment (Pharmaceutical Benefits) Bill 2015 will allow substitution of biosimilar drugs at the pharmacy level.

Under this legislation, the pharmacist would be able to substitute Basaglar insulin for Lantus insulin without consultation with the patient’s doctor or health professional team. The Product Information for Basaglar insulin, approved by the TGA, is reported to effectively rule out pharmacy level substitution saying "The level of comparability that has been shown is not sufficient to designate this product as a generic version of Lantus. Replacement of Lantus with Basaglar, or vice versa, should take place only under strict medical supervision," This warning appears to conflict with the recent PBS reform package of legislation which puts responsibility for determining pharmacy level substitution in the hands of the PBAC which has been reported to support a default position of allowing pharmacy level substitution.

Biosimilars are complex mixtures of isoforms that are by nature complex. Unlike generics, they are different in composition from their originator, and cannot be identical to the originator drug.

There is currently insufficient evidence with respect to clinical equivalence of Basaglar and Lantus and pharmacodynamic and pharmacokinetic similarity is not necessarily enough to assume clinical equivalence.

The case of changing from porcine to human insulin in the 1980’s illustrates the concerns. Theoretically, there was not expected to be any issue with direct substitution of porcine with human insulin based on pharmacodynamic and pharmacokinetic similarity. However, there were many patient reports of people experiencing hypoglycaemia unawareness with human insulin leading to increased hospitalization and accidents. This was supported by peer-reviewed publications and extensive evidence.

This experience led to caution with the subsequent change from human to analogue insulins. We should be equally cautious in considering biosimilar insulin substitution.

There is not yet any evaluation of the impact on a person’s management of their diabetes if they alternate between originator and biosimilar insulin over the long term. Switching to biosimilar insulin could have a negative impact given the long-term nature of insulin therapy and this has not yet been examined sufficiently to inform a decision on substitutions.

There have been reports that the PBAC could allow the substitution of biosimilars unless companies can provide evidence demonstrating they should not be substituted. This shift in the 'burden of proof' is concerning. Medicines should not be subject to considerations that rely on the 'absence of data' to prove their safety.
Other Clinical Issues
There are important considerations which are crucial to the wellbeing of people with diabetes who need insulin therapy.

For example, the main delivery source of insulin in Australia is through high-precision, pen-delivery devices designed to deliver exact doses of insulin. This is critical to patient wellbeing. Subtle differences between insulin and biosimilar insulin may not be clinically significant but it can render a delivery device less effective or ineffective. This could have major consequences for a person’s health.

Each manufacturers’ devices are different and patients are provided specific training from healthcare professionals about their specific device when they commence insulin therapy. Pharmacy staff are often not familiar with, nor trained in the use of, these devices.

The proposed changes mean a patient could have their insulin switched at the pharmacy level, without the knowledge of their diabetes healthcare team. That means, in addition to an alternate insulin, patients could be supplied with different devices which they are not trained to use.

Changes in dosage amounts between the original and the biosimilar could also cause confusion and inappropriate dosage.

The pharmacist dispensing the biosimilar insulin may not be aware of the previous reactions the patient has had with alternate insulin sources.

Role of Biosimilar Insulins
We recognize there are scenarios where it is appropriate to consider the use of Basaglar insulin as follows.

- when insulin therapy is being commenced for the first time
- when other insulins have been tried, and the biosimilar is deemed a suitable alternative by the patient’s doctor.

However, any pharmacy level substitution of biosimilar insulins should not be considered until there is sufficient clinical experience and evidence developed in Australia about switching conducted under medical supervision.

We look forward to working with the PBAC to ensure that as biosimilar drugs are considered, efficacy and safety issues remain paramount and appropriate measures are in place to safeguard the health of Australians with diabetes.

Updated: 11 September 2015